Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study - PubMed (original) (raw)
. 2004 Nov 15;104(10):3046-51.
doi: 10.1182/blood-2004-03-0897. Epub 2004 Jun 29.
Affiliations
- PMID: 15226189
- DOI: 10.1182/blood-2004-03-0897
Free article
Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study
Jeppe Frederiksen et al. Blood. 2004.
Free article
Abstract
Hyperhomocysteinemia is associated with ischemic cardiovascular disease (ICD) and venous thromboembolism (VTE). We tested the hypothesis that methylenetetrahydrofolate reductase (MTHFR) C677T homozygosity with hyperhomocysteinemia is associated with ICD and VTE. First, 9238 randomly selected whites from the general population were followed for 23 years. Second, 2125 whites with ischemic heart disease and 836 whites with ischemic cerebrovascular disease were compared with 7568 controls from the general population. Plasma homocysteine was elevated 25% in homozygotes versus noncarriers (P < .001) and 19% in ICD/VTE cases versus controls (P < .001). In prospective studies adjusted hazard ratios for ICD and VTE for homozygotes versus noncarriers did not differ from 1.0. Furthermore, MTHFR C677T homozygosity was not associated with increased risk of ICD or VTE in subgroups after stratification for sex, age, cholesterol, high-density lipoprotein cholesterol, lipoprotein(a), fibrinogen, triglycerides, body mass index, smoking, diabetes mellitus, hypertension, and factor V Leiden genotype. Finally, in case-control studies odds ratios for ischemic heart disease and ischemic cerebrovascular disease in homozygotes versus noncarriers did not differ from 1.0. In conclusion, MTHFR C677T homozygosity with hyperhomocysteinemia is not associated with ICD or VTE; however, ICD/VTE is associated with hyperhomocysteinemia. Therefore, ICD and VTE may cause hyperhomocysteinemia, rather than vice versa.
Comment in
- Hyperhomocysteinemia: cause or effect of disease?
Marcucci R, Gori AM, Abbate R. Marcucci R, et al. Blood. 2005 Apr 15;105(8):3382-3; author reply 3383-4. doi: 10.1182/blood-2004-12-4610. Blood. 2005. PMID: 15802548 No abstract available.
Similar articles
- Association study of methylenetetrahydrofolate reductase C677T mutation with cerebral venous thrombosis in an Iranian population.
Ghaznavi H, Soheili Z, Samiei S, Soltanpour MS. Ghaznavi H, et al. Blood Coagul Fibrinolysis. 2015 Dec;26(8):869-73. doi: 10.1097/MBC.0000000000000292. Blood Coagul Fibrinolysis. 2015. PMID: 26083986 - C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients.
Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. Gemmati D, et al. Haematologica. 1999 Sep;84(9):824-8. Haematologica. 1999. PMID: 10477457 - The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C>T) and elevated plasma homocysteine levels in a U.S. pediatric population with incident thromboembolism.
Joachim E, Goldenberg NA, Bernard TJ, Armstrong-Wells J, Stabler S, Manco-Johnson MJ. Joachim E, et al. Thromb Res. 2013 Aug;132(2):170-4. doi: 10.1016/j.thromres.2013.06.005. Epub 2013 Jul 16. Thromb Res. 2013. PMID: 23866722 Free PMC article. - MTHFR A1298C and C677T Polymorphisms Are Associated with Increased Risk of Venous Thromboembolism: A Retrospective Chart Review Study.
Liu F, Silva D, Malone MV, Seetharaman K. Liu F, et al. Acta Haematol. 2017;138(4):208-215. doi: 10.1159/000480447. Epub 2017 Dec 7. Acta Haematol. 2017. PMID: 29212064 Review. - Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD.
Nakai K, Itoh C, Nakai K, Habano W, Gurwitz D. Nakai K, et al. Am J Cardiovasc Drugs. 2001;1(5):353-61. doi: 10.2165/00129784-200101050-00005. Am J Cardiovasc Drugs. 2001. PMID: 14728017 Review.
Cited by
- The 677C > T variant in methylenetetrahydrofolate reductase causes morphological and functional cerebrovascular deficits in mice.
Reagan AM, Christensen KE, Graham LC, Bedwell AA, Eldridge K, Speedy R, Figueiredo LL, Persohn SC, Bottiglieri T, Nho K, Sasner M, Territo PR, Rozen R, Howell GR. Reagan AM, et al. J Cereb Blood Flow Metab. 2022 Dec;42(12):2333-2350. doi: 10.1177/0271678X221122644. Epub 2022 Sep 1. J Cereb Blood Flow Metab. 2022. PMID: 36050860 Free PMC article. - Methylenetetrahydrofolate Reductase Polymorphism (rs1801133) and the Risk of Hypertension among African Populations: A Narrative Synthesis of Literature.
Mabhida SE, Muhamed B, Sharma JR, Apalata T, Nomatshila S, Mabasa L, Benjeddou M, Masilela C, Ziqubu K, Shabalala S, Johnson R. Mabhida SE, et al. Genes (Basel). 2022 Apr 1;13(4):631. doi: 10.3390/genes13040631. Genes (Basel). 2022. PMID: 35456437 Free PMC article. Review. - Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks.
Raghubeer S, Matsha TE. Raghubeer S, et al. Nutrients. 2021 Dec 20;13(12):4562. doi: 10.3390/nu13124562. Nutrients. 2021. PMID: 34960114 Free PMC article. Review. - Association Between MTHFR Polymorphisms and the Risk of Essential Hypertension: An Updated Meta-analysis.
Meng H, Huang S, Yang Y, He X, Fei L, Xing Y. Meng H, et al. Front Genet. 2021 Nov 26;12:698590. doi: 10.3389/fgene.2021.698590. eCollection 2021. Front Genet. 2021. PMID: 34899823 Free PMC article. Review. - Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization.
Fu L, Li YN, Luo D, Deng S, Wu B, Hu YQ. Fu L, et al. J Clin Hypertens (Greenwich). 2019 Dec;21(12):1879-1894. doi: 10.1111/jch.13737. Epub 2019 Nov 25. J Clin Hypertens (Greenwich). 2019. PMID: 31769183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical